Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Advantis Corp. Moves Forward With Pet Division


Posted on: 02 Apr 18

NEWPORT BEACH, CA , April 02, 2018 (GLOBE NEWSWIRE) -- ADVANTIS CORPORATION (OTC PINK: ADVT) announced it is moving forward with plans to establish a pet division that will create and market a proprietary line of CBD-infused pet supplements and therapeutic pet edibles. The company has been working on and testing this line of products for the past two years, according to company Legal Counsel, Geoffrey Broderick, Jr.

“It was among the first projects I put together when I came on board over two years ago,” Broderick explained. “My father, known in the industry as Doctor Geoff, has dedicated over fifty years of his life as a Veterinarian developing treatments, cures, and therapies for animals. Throughout his extensive career, he developed a clinically-proven medication (Cornucopia Superfood) to treat autoimmune related diseases and pet cancer. He loves animals. He has seen how CBD has the ability to extend lives and provide comfort, which is why he has been helping us develop a serious solution in this industry.” Broderick, who has worked with his father, Dr. R.G. Broderick, over several years, established a strategy to develop, test, and manufacture these perfected antioxidant superfood supplements by carefully blending in CBD, which is known for its therapeutic properties. “Over twenty-six years ago I began developing this very nutraceutical solution with my Dad,” Broderick beamed. “It’s kind of nice that its’ come full circle and we have a chance to work together again.”

According to Advantis CEO, Darren Cherry, the future of the coming pet division looks bright. “We’re lucky to be allied with such a well-known icon in the pet supplement, nutraceutical, and pet-med world. He literally invented this industry with his developments over twenty-five years ago,” Cherry stated. “We have a CBD-infused pet supplement that no one can replicate, due to the specific process and ingredients. This is Geoffrey’s baby; this is his division to build. We already have our current partners excited to test market this summer, and we’re confident that this will be a high margin product due to the extensive sweat equity that went into developing this amazing all-natural therapeutic supplement.” Details of the formulae remain closely held, however Cherry said that more details will be revealed as they get closer to market. “We are developing plans to debut our first product this summer, and are collaborating with Doctor Geoff to tap into the market that he is so famous in. I am confident in the Brodericks’ ability to bring this vision to fruition... and expand Advantis’ footprint nationwide, as a leader in all kinds of the highest quality CBD products.” Cherry concluded his comments by suggesting there will be several announcements over then next year as the Pet Division develops.

Advantis wishes to thank Investors Hangout for mentioning the company in their podcast.

Links to Advantis websites can be found at advantiscorp.comrosin6.comelixicure.com, and amstercan.com

About Advantis Corporation
Advantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. The company additionally establishes partnerships with businesses that develop and sell proprietary pain management, and consumer products and services. 

Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act.

CONTACT: For further information, contact:  Media Relations Contact Name: Woo Kim, Director Organization: Advantis Corporation  Phone: 949-354-3585 Address: 1048 Irvine Ave. #900 Newport Beach, CA 92660 E-mail: info@advantiscorp.comGlobeNewswire
globenewswire.com

Last updated on: 03/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.